Patient-specific neoantigen peptide (TSNA)

Patient-specific neoantigen peptides are unique protein fragments derived from non-synonymous somatic mutations, such as single nucleotide variants or frameshifts, that occur exclusively within a patient's tumor cells (Schumacher & Schreiber, 2015). These peptides are processed by the cellular machinery and presented on the cell surface by Major Histocompatibility Complex (MHC) molecules, serving as highly specific markers for the immune system (Sahin & Türeci, 2018). Because these antigens are absent from normal tissues, they bypass central thymic tolerance, making them exceptionally immunogenic and reducing the risk of autoimmune toxicity compared to shared tumor-associated antigens (Blass & Ott, 2021). In clinical practice, these peptides are identified through whole-exome sequencing and bioinformatic algorithms to design personalized cancer vaccines or to engineer adoptive T-cell therapies. This approach leverages the patient's own immune system to mount a precise and durable anti-tumor response tailored to the unique genetic landscape of their malignancy (Ott et al., 2017). By targeting the 'mutanome,' these therapies represent a cornerstone of precision oncology, particularly for high-mutation-burden cancers.

Other names

Tumor-specific neoantigenNeoepitopeSomatic mutation-derived antigenPersonalized neoantigenTumor-specific antigen

Induction of de novo T-cell responses and expansion of pre-existing memory T-cells by presenting tumor-specific mutated epitopes on Major Histocompatibility Complex (MHC) molecules, which are recognized by T-cell receptors (TCRs) to trigger targeted cytotoxicity against malignant cells (Schumacher & Schreiber, 2015; Blass & Ott, 2021).